Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory
The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.
1. A method of treating a pathological disorder mediated by IL-17A in a subject, said method comprising administering to said subject the antibody or antigen-binding portion thereof, comprising a heavy chain variable region (V H ) and a light chain variable region (V L );
a. wherein said V H comprises the three CDRs of the amino acid sequence set forth as SEQ ID NO:12 and wherein said V L comprises the three CDRs of the amino acid sequence set forth as SEQ ID NO:43;
b. wherein said V H comprises, in sequence, the three Complimentarily Determining Regions (CDRs) set forth as amino acid sequences SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:3 and wherein said V L comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:42, SEQ ID NO:23, SEQ ID NO:11; or
c. wherein said V H comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and wherein said V L comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:41, SEQ ID NO:5, SEQ ID NO:6.
2. The method according to claim 1 , wherein the disorder is an inflammatory disorder or condition.
3. The method according to claim 1 , wherein the disorder is arthritis, rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, uveitis, systemic lupus erythematosus (SLE), lupus, nephritis, asthma, multiple sclerosis or cystic fibrosis.
4. The method according to claim 1 , wherein the disorder is ankylosing spondylitis, Reiter syndrome, reactive arthritis, psoriatic arthritis, juvenile idiopathic arthritis, enterophathis arthritis, enthesitis, myasthenia gravis, psoriasis, atopic dermatitis, contact dermatitis, bullous diseases of the skin and mucous membranes, or cancer.
5. The method according to claim 1 , wherein the isolated antibody or antigen-binding portion thereof is a human antibody or antigen-binding portion thereof, a monoclonal antibody or antigen-binding portion thereof, a chimeric antibody or antigen-binding portion thereof, a humanized antibody or antigen-binding portion thereof, a F(ab′)2 fragment, a dAb fragment, a Fab fragment, or a Fv fragment.
6. The method according to claim 5 , wherein the isolated antibody or antigen-binding portion thereof is a monoclonal antibody, a chimeric antibody, or a humanized antibody.
7. The method according to claim 5 , wherein the isolated antibody or antigen-binding portion thereof is a human antibody.
8. The method according to claim 6 , wherein the human antibody comprises a heavy chain and a light chain, wherein said heavy chain comprises the amino acid sequence set forth as SEQ ID NO:14 and wherein said light chain comprises the amino acid sequence set forth as SEQ ID NO:44.